With the advent of novel ALK inhibitors utilized in sequence, the survival of patients with ALK-rearranged tumors has improved dramatically. This case series serves to compare tumor response rates and long-term survival outcomes among four patients treated with ensartinib over the course of four years at our institution.We found that ensartinib is well tolerated and has clinical activity in advanced ALK-rearranged NSCLC patients with brain metastases, despite previously progressing on crizotinib, with durable post-ensartinib survival on subsequent next-generation ALK inhibitors such as brigatinib and lorlatinib. READ ARTICLE
Journal of Thoracic Oncology DOI:10.5455/jpma.3142. PMID: 32296229.
Authors: H. Kim, P. Vu, K. Harrow, C. Liang, G. Selvaggi, E. Weihe, W. Mitchell, L. Bazhenova, S. Patel
